All In Biotech

Drug Trial Radar · NCT04053270

Multicentre Phase III Erythropoietic Protoporphyria Study

A Phase III, Multicentre, Randomised, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Subcutanenous Bioresorbable CUV1647 Implants in Patients With Erythropoietic Protoporphyria (EPP)

Last checked: Nov 20, 2026Latest source record: Oct 10, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

100

Actual

Start

May 2007

Primary completion

Dec 9, 2009

Study completion Dec 9, 2009

Sponsor

Sponsor type
Industry
First posted
Aug 12, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a phase III, multicentre, randomised, double-blind, placebo-controlled study, to evaluate the safety and efficacy of subcutaneous bioresorbable afamelanotide implants in patients with Erythropoietic Protoporphyria (EPP). The study was conducted with two parallel study arms with crossover between treatments every 60 days. Eligible patients were randomised to a treatment group, and received implants of active treatment (afamelanotide 16mg) or placebo, in an alternating crossover fashion according to the following dosing regime: * Group A was administered active implants on Days 0, 120, 240 and placebo implants on Days 60, 180, 300 * Group B was administered placebo implants on Days 0, 120, 240 and active implants on Days 60, 180, 300

Conditions

  • Erythropoietic Protoporphyria

Interventions

  • AfamelanotideDrug

    16mg subcutaneous implant

  • PlaceboDrug

    Placebo subcutaneous implant

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cumulative Number of Days of Phototoxic Reactions (Study Efficacy Population)Time frame: 0-360 days or Early Termination
  2. The Mean Number of Phototoxic Reactions (Study Efficacy Population)Time frame: 0-360 days or Early Termination

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.